Millipore Sigma Vibrant Logo

MAB348 Anti-APP A4 Antibody, a.a. 66-81 of APP {NT}, clone 22C11

View Products on
50 µg  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
Request Pricing
Limited AvailabilityLimited Availability
Limited Quantities Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Special Offers


      Contact Customer Service


      Replacement Information

      Key Specifications Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      Ca, H, M, Mk, Po, R, FICC, IF, IHC, IH(P), WBMPurifiedMonoclonal Antibody
      Catalogue NumberMAB348
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionAnti-APP A4 Antibody, a.a. 66-81 of APP {NT}, clone 22C11
      Alternate Names
      • APP
      Background InformationDeposits of amyloid protein in senile plaques near nerve processes are found in the brains of aged humand and cases of Alzheimer's Disease. The principle component of this extracellular amyloid is beta A4, a 4 kDa peptide derived from a larger amyloid precursor protein (APP), which is widely expressed in the brain and body. The creation, transport and function of these proteins is currently an active area of research.
      Product Information
      • Brain tissue, brain cell lysates
      PresentationProtein A Purified mouse immunoglobulin in 20 mM sodium phosphate, 250 mM NaCl, pH. 7.6, with 0.1% sodium azide as a preservative.
      Quality LevelMQ100
      ApplicationAnti-APP A4 Antibody, a.a. 66-81 of APP {N-terminus}, clone 22C11 is an antibody against Alzheimer Precursor Protein A4 for use in IF, IH, IH(P) & WB with more than 85 product citations.
      Key Applications
      • Immunocytochemistry
      • Immunofluorescence
      • Immunohistochemistry
      • Immunohistochemistry (Paraffin)
      • Western Blotting
      Application NotesImmunofluorescence

      Immunohistochemistry: 5-10 μg/mL on 4% paraformaldehyde/15% picric acid perfused and fixed rat spinal cord. 22C11 also works in paraffin embedded tissues but at lower dilutions (1:10-1:20).

      Western blot: reducing conditions, 10μg/ml.

      Optimal working dilutions and protocols must be determined by the end user.
      Biological Information
      ImmunogenPurified recombinant Alzheimer precursor A4 (pre A4695) fusion protein.
      Epitopea.a. 66-81 of APP {N-terminus}
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      SpecificityReacts with pre-A4. The antibody recognizes amino acids 66-81 of the N-terminus on the pre-A4 molecule (Hilbich et al., 1993). 22C11 recognizes all three isoforms of APP, immature ~110kDa, sAPP ~120kDa, and mature ~130kDa (Hoffmann et al., 2000). The antibody is known to cross react with APLP2 (Slunt, 1994).
      Species Reactivity
      • Canine
      • Human
      • Mouse
      • Monkey
      • Pig
      • Rat
      • Fish
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThis gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene.
      Gene Symbol
      • APP
      • PN-II
      • AD1
      • ABETA
      • CTFgamma
      • APPI
      • ABPP
      • A4
      • CVAP
      • PN2
      • PreA4
      • AAA
      Purification MethodProtein A Purfied
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P05067 # The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.
      SIZE: 770 amino acids; 86943 Da
      SUBUNIT: Binds, via its C-terminus, to the PID domain of several cytoplasmic proteins, including APBB family members, the APBA family, MAPK8IP1, SHC1 and, Numb and Dab1 (By similarity). Binding to Dab1 inhibits its serine phosphorylation (By similarity). Also interacts with GPCR-like protein BPP, FPRL1, APPBP1, IB1, KNS2 (via its TPR domains) (By similarity), APPBP2 (via BaSS) and DDB1. In vitro, it binds MAPT via the MT-binding domains (By similarity). Associates with microtubules in the presence of ATP and in a kinesin-dependent manner (By similarity). Interacts, through a C-terminal domain, with GNAO1. Amyloid beta-42 binds CHRNA7 in hippocampal neurons. Beta-amyloid associates with HADH2. Soluble APP binds, via its N-terminal head, to FBLN1. Interacts with CPEB1 (By similarity).
      SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein. Note=Cell surface protein that rapidly becomes internalized via clathrin-coated pits. During maturation, the immature APP (N-glycosylated in the endoplasmic reticulum) moves to the Golgi complex where complete maturation occurs (O- glycosylated and sulfated). After alpha-secretase cleavage, soluble APP is released into the extracellular space and the C- terminal is internalized to endosomes and lysosomes. Some APP accumulates in secretory transport vesicles leaving the late Golgi compartment and returns to the cell surface. Gamma-CTF(59) peptide is located to both the cytoplasm and nuclei of neurons. It can be translocated to the nucleus through association with Fe65. Beta- APP42 associates with FRPL1 at the cell surface and the complex is then rapidly internalized. APP sorts to the basolateral surface in epithelial cells. During neuronal differentiation, the Thr-743 phosphorylated form is located mainly in growth cones, moderately in neurites and sparingly in the cell body. Casein kinase phosphorylation can occur either at the cell surface or within a post-Golgi compartment.
      TISSUE SPECIFICITY: Expressed in all fetal tissues examined with highest levels in brain, kidney, heart and spleen. Weak expression in liver. In adult brain, highest expression found in the frontal lobe of the cortex and in the anterior perisylvian cortex- opercular gyri. Moderate expression in the cerebellar cortex, the posterior perisylvian cortex-opercular gyri and the temporal associated cortex. Weak expression found in the striate, extra- striate and motor cortices. Isoform APP695 is the predominant form in neuronal tissue, isoform APP751 and isoform APP770 are widely expressed in non-neuronal cells. Isoform APP751 is the most abundant form in T-lymphocytes. Appican is expressed in astrocytes.
      DOMAIN: SwissProt: P05067 The basolateral sorting signal (BaSS) is required for sorting of membrane proteins to the basolateral surface of epithelial cells. & The NPXY sequence motif found in many tyrosine- phosphorylated proteins is required for the specific binding of the PID domain. However, additional amino acids either N- or C- terminal to the NPXY motif are often required for complete interaction. The PID domain-containing proteins which bind APP require the YENPTY motif for full interaction. These interactions are independent of phosphorylation on the terminal tyrosine residue. The NPXY site is also involved in clathrin-mediated endocytosis.
      PTM: Proteolytically processed under normal cellular conditions. Cleavage by alpha-secretase or alternatively by beta-secretase leads to generation and extracellular release of soluble APP peptides, S-APP-alpha and S-APP-beta, respectively, and the retention of corresponding membrane-anchored C-terminal fragments, C83 and C99. Subsequent processing of C83 by gamma-secretase yields P3 peptides. This is the major secretory pathway and is non-amyloidogenic. Alternatively, presenilin/nicastrin-mediated gamma-secretase processing of C99 releases the amyloid beta proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42), major components of amyloid plaques, and the cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59). & Proteolytically cleaved by caspases during neuronal apoptosis. Cleavage at Asp-739 by either caspase-6, -8 or -9 results in the production of the neurotoxic C31 peptide and the increased production of beta-amyloid peptides. & N- and O-glycosylated. O-linkage of chondroitin sulfate to the L-APP isoforms produces the APP proteoglycan core proteins, the appicans. The chondroitin sulfate chain of appicans contains 4-O-sulfated galactose in the linkage region and chondroitin sulfate E in the repeated disaccharide region (By similarity). & Phosphorylation in the C-terminal on tyrosine, threonine and serine residues is neuron-specific. Phosphorylation can affect APP processing, neuronal differentiation and interaction with other proteins. Phosphorylated on Thr-743 in neuronal cells by Cdc5 kinase and Mapk10, in dividing cells by Cdc2 kinase in a cell- cycle dependent manner with maximal levels at the G2/M phase and, in vitro, by GSK-3-beta. The Thr-743 phosphorylated form causes a conformational change which reduces binding of Fe65 family members. Phosphorylation on Tyr-757 is required for SHC binding. Phosphorylated in the extracellular domain by casein kinases on both soluble and membrane-bound APP. This phosphorylation is inhibited by heparin. & Extracellular binding and reduction of copper, results in a corresponding oxidation of Cys-144 and Cys-158, and the formation of a disulfide bond. In vitro, the APP-Cu(+) complex in the presence of hydrogen peroxide results in an increased production of beta-amyloid-containing peptides.
      DISEASE: SwissProt: P05067 # Defects in APP are a cause of autosomal dominant Alzheimer disease (AD) [MIM:104300]. AD is the most prevelant form of dementia, characterized by neurofibrillary tangles and amyloid plaques deposition in the brain. Identical lesions occur in the neurons of aged Down syndrome but at an earlier age than in AD. The major constituent of these neuritic plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. Mutations occurring at the beta-amyloid N-terminal, such as the Swedish double mutation, appear to increase levels of beta-amyloid by facilitating beta-secretase cleavage resulting in elevated levels of both beta-APP42 and beta-APP40. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31, are also implicated in AD neuronal death. Alzheimer disease caused by mutations in APP is a rare occurrence and usually causes the familial or early-onset form of the disease (FAD). Flemish-type AD is characterized by, in addition to presenile dementia, cerebral hemorrhaging due to cerebral amyloid angiopathy which is similar to, but distinct from, cerebroarterial amyloidosis Dutch type. Only about 5% of all cases of Alzheimer disease are caused by FAD mutations, the rest are sporadic. & Defects in APP are the cause of hereditary cerebral hemorrhage with amyloidosis Dutch type (HCHWAD) [MIM:609065]. HCHWAD is characterized by amyloid deposits in cerebral vessels. The principal clinical characteristics are recurring cerebral hemorrhages, sometimes preceded by migrainous headaches or mental cleavage. Beta-APP40 is the predominant form of cerebrovascular amyloid. & Defects in APP are the cause of hereditary cerebroarterial amyloidosis Iowa type [MIM:605714]. Hereditary cerebroarterial amyloidosis Iowa type is an autosomal dominant dementia beginning in the sixth or seventh decade of life. The patients have progressive aphasic dementia, leukoencephalopathy, and occipital calcifications. They do not present cerebral hemorrhaging.
      SIMILARITY: Belongs to the APP family. & Contains 1 BPTI/Kunitz inhibitor domain.
      MISCELLANEOUS: Chelation of metal ions, notably copper, iron and zinc, can induce histidine-bridging between beta-amyloid molecules resulting in beta-amyloid-metal aggregates. The affinity for copper is much higher than for other transient metals and is increased under acidic conditions. Extracellular zinc-binding increases binding of heparin to APP and inhibits collagen-binding.
      Molecular Weight110/120/130 kDa
      Physicochemical Information
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsMaintain for 1 year at 2–8°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
      Packaging Information
      Material Size50 µg
      Transport Information
      Supplemental Information


      Anti-APP A4 Antibody, a.a. 66-81 of APP {NT}, clone 22C11 SDS


      Safety Data Sheet (SDS) 

      Anti-APP A4 Antibody, a.a. 66-81 of APP {NT}, clone 22C11 Certificates of Analysis

      TitleLot Number
      Anti-Alzheimer Precursor Protein A4, clone 22C11 - 2382168 2382168
      Anti-Alzheimer Precursor Protein A4, clone 22C11 - 2024170 2024170
      Anti-Alzheimer Precursor Protein A4, -2517783 2517783
      Anti-Alzheimer Precursor Protein A4, -2578075 2578075
      Anti-Alzheimer Precursor Protein A4, -2591337 2591337
      Anti-Alzheimer Precursor Protein A4, -2636695 2636695
      Anti-Alzheimer Precursor Protein A4, -2716738 2716738
      Anti-Alzheimer Precursor Protein A4, -2736591 2736591
      Anti-Alzheimer Precursor Protein A4, -2794907 2794907
      Anti-Alzheimer Precursor Protein A4, -2811987 2811987


      Reference overviewApplicationSpeciesPub Med ID
      Antroquinonol Lowers Brain Amyloid-β Levels and Improves Spatial Learning and Memory in a Transgenic Mouse Model of Alzheimer's Disease.
      Chang, WH; Chen, MC; Cheng, IH
      Scientific reports  5  15067  2015

      Show Abstract
      26469245 26469245
      Peptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce ß-amyloid in Alzheimer's disease.
      Dewji, NN; Singer, SJ; Masliah, E; Rockenstein, E; Kim, M; Harber, M; Horwood, T
      PloS one  10  e0122451  2015

      Show Abstract
      25923432 25923432
      Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer's disease mouse model.
      Nygaard, HB; Kaufman, AC; Sekine-Konno, T; Huh, LL; Going, H; Feldman, SJ; Kostylev, MA; Strittmatter, SM
      Alzheimer's research & therapy  7  25  2015

      Show Abstract
      25945128 25945128
      Characterization of a Novel Mouse Model of Alzheimer's Disease--Amyloid Pathology and Unique β-Amyloid Oligomer Profile.
      Liu, P; Paulson, JB; Forster, CL; Shapiro, SL; Ashe, KH; Zahs, KR
      PloS one  10  e0126317  2015

      Show Abstract
      25946042 25946042
      Contribution of Schwann Cells to Remyelination in a Naturally Occurring Canine Model of CNS Neuroinflammation.
      Kegler, K; Spitzbarth, I; Imbschweiler, I; Wewetzer, K; Baumgärtner, W; Seehusen, F
      PloS one  10  e0133916  2015

      Show Abstract
      26196511 26196511
      Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence.
      Morancho, B; Martínez-Barriocanal, Á; Villanueva, J; Arribas, J
      Breast cancer research : BCR  17  106  2015

      Show Abstract
      26260680 26260680
      Alzheimer's Disease-Related Protein Expression in the Retina of Octodon degus.
      Du, LY; Chang, LY; Ardiles, AO; Tapia-Rojas, C; Araya, J; Inestrosa, NC; Palacios, AG; Acosta, ML
      PloS one  10  e0135499  2015

      Show Abstract
      26267479 26267479
      Localization of reelin signaling pathway components in murine midbrain and striatum.
      Sharaf, A; Rahhal, B; Spittau, B; Roussa, E
      Cell and tissue research  359  393-407  2015

      Show Abstract
      Mouse25418135 25418135
      The Golgi-Localized γ-Ear-Containing ARF-Binding (GGA) Proteins Alter Amyloid-β Precursor Protein (APP) Processing through Interaction of Their GAE Domain with the Beta-Site APP Cleaving Enzyme 1 (BACE1).
      von Einem, B; Wahler, A; Schips, T; Serrano-Pozo, A; Proepper, C; Boeckers, TM; Rueck, A; Wirth, T; Hyman, BT; Danzer, KM; Thal, DR; von Arnim, CA
      PloS one  10  e0129047  2015

      Show Abstract
      26053850 26053850
      Experimental microembolism induces localized neuritic pathology in guinea pig cerebrum.
      Li, JM; Cai, Y; Liu, F; Yang, L; Hu, X; Patrylo, PR; Cai, H; Luo, XG; Xiao, D; Yan, XX
      Oncotarget  6  10772-85  2015

      Show Abstract
      25871402 25871402


      SNAP i.d. 2.0 System Brochure

      Related Products & Applications

      Alternative Packsize

      Catalog Number Description  
      MAB348-100UL Anti-APP A4 Antibody, a.a. 66-81 of APP (NT), clone 22C11 Show Pricing & Availability

      Product Families


      Life Science Research > Antibodies and Assays > Primary Antibodies